Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cephalothin sodium -

United States - English - NLM (National Library of Medicine)

cardinal health - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 0.2 g in 5 ml - neut (4% sodium bicarbonate additive solution) is indicated for use as an additive to raise the ph of acid solutions administered intravenously to reduce the incidence of chemical phlebitis and patient discomfort due to vein irritation at or near the site of infusion. not for use as a systemic alkalizer. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefalotin sodium, quantity: 1.058 g (equivalent: cefalotin, qty 1 g) - injection, powder for - excipient ingredients: sodium bicarbonate - indications: cephalothin sodium for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. culture and susceptibility studies should be performed. however, therapy may be instituted before results of susceptibility studies are obtained (see pharmacology: microbiology). respiratory tract: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, klebsiella, and h. influenzae. skin and soft tissue: infections, including peritonitis, caused by staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, e.coli, pr. mirabilis and klebsiella. genitourinary tract: infections caused by e. coli, pr. mirabilis and klebsiella. septicaemia, including endocarditis: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, s. viridans, e. coli, pr. mirabilis and klebsiella. bone and joint: infection caused by staphylococci (penicillinase and non-penicillinase producing). prophylactically in vaginal hysterectomy, head and neck surgery, insertion of prosthetic heart valves, and prosthetic arthroplasty. cephalothin is not recommended for gastrointestinal procedures or other sites where anaerobic organisms such as bacteriodes tend to prevail. dosage is required pre-, intra-and postoperatively (i.e perioperatively, see dosage and administration). if signs of postoperative infection develop, specimens should be cultured to identify the causative organism so that appropriate therapy can be instituted. note: if the susceptibility tests show that the causative organism is resistant to cephalothin, other appropriate antibiotic therapy should be instituted.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cefotaxime sodium, quantity: 2.096 g - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms: infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta lactamase producing strains of n.gonorrhoeae). ear, nose and throat infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates) pending the availabiliy of culture and sensitivity results. in adults, the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infe

United States - English - NLM (National Library of Medicine)

hospira, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 0.2 g in 5 ml - neut (4% sodium bicarbonate additive solution) is indicated for use as an additive to raise the ph of acid solutions administered intravenously to reduce the incidence of chemical phlebitis and patient discomfort due to vein irritation at or near the site of infusion. not for use as a systemic alkalizer. none known.

United States - English - NLM (National Library of Medicine)

cardinal health - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - neut (4% sodium bicarbonate additive solution) is indicated for use as an additive to raise the ph of acid solutions administered intravenously to reduce the incidence of chemical phlebitis and patient discomfort due to vein irritation at or near the site of infusion. not for use as a systemic alkalizer. none known.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim roxane laboratories - diclofenac sodium (unii: qtg126297q) - tablet, delayed release - 50 mg - diclofenac sodium delayed-release tablets are indicated for the acute and chronic treatment of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. diclofenac sodium delayed-release tablets are contraindicated in patients with hypersensitivity to the product. diclofenac should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to diclofenac have been reported in such patients.

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun medical limited - sodium chloride; potassium chloride; sodium lactate solution; calcium chloride dihydrate - solution for infusion - per cent - solutions affecting the electrolyte balance; electrolytes

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun medical limited - sodium chloride potassium chloride sodium lactate solution calcium chloride dihydrate - solution for infusion - 500ml,1000 %v/v

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - colistimethate sodium, quantity: 1 million iu - inhalation - excipient ingredients: - tadim powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible pseudomonas aeruginosa in patients with cystic fibrosis. consideration should be given to official guidance on the appropriate use of antibacterial agents.